查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1844096

乳癌診斷市場按技術、產品、生物標記、樣本類型和最終用戶分類－2025-2032年全球預測

Breast Cancer Diagnostics Market by Technology, Product, Biomarker, Sample Type, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，乳癌診斷市場規模將達到 130.6 億美元，複合年成長率為 8.02%。

主要市場統計數據
基準年 2024 70.4億美元
預計年份：2025年 76億美元
預測年份：2032年 130.6億美元
複合年成長率 (%) 8.02%

簡明扼要地介紹不斷發展的乳癌診斷格局，重點在於臨床效用和營運轉型之間的交集。

乳癌診斷正經歷快速變革時期，主要得益於採樣技術、組織分析、影像技術和分子譜分析技術的同步發展。新的工具正在重塑從初步篩檢到最終診斷和治療方法分層的臨床流程，而放射科、病理科和分子實驗室之間的多學科合作對於提供精準醫療服務也變得日益重要。更豐富的資料流，包括數位乳房斷層合成影像、用於演算法分析的數位化免疫組化切片以及來自新一代定序的基因組特徵，正在增強臨床決策能力。

在此背景下，相關人員必須協調營運限制與不斷發展的醫療標準。不同終端使用者（癌症研究中心、診斷實驗室、醫院和專科診所）的採納動態各不相同，並受到耗材、儀器、軟體和服務等產品細分的影響。檢體類型（血液、血清和組織）的考量持續影響工作流程設計和檢體物流。總而言之，診斷領域需要一項綜合策略規劃，以平衡臨床效用、工作流程效率和永續的報銷管道。

影像、組織取樣、組織病理學自動化和分子譜分析的進展如何系統性地重新定義診斷路徑和臨床工作流程

多項變革正在改變乳癌的檢測、分類和監測方式。首先，影像技術正從類比技術向數位轉型，數位乳房斷層合成和先進的乳房X光乳房X光攝影與磁振造影（MRI）和超音波相結合，以增強病灶的定性和分診能力。這些影像技術擴大與計算工具相結合，以輔助放射科醫生的解讀並確定切片檢查的優先順序。其次，隨著穿刺和手術技術的不斷改進，切片檢查方法也日趨多樣化，旨在最大限度地保留組織，同時實現全面的後續檢測，從而影響實驗室的工作流程和耗材需求。

同時，組織病理學正隨著免疫組織化學和自動化染色系統的日益普及而不斷發展，這些技術提高了檢測通量和可重複性。螢光雜合反應、 PCR變體和新一代測序（包括靶向測序和全基因組測序）提供了詳細的生物標記資訊，從而指導治療決策。與這些技術變革相輔相成的是以數據分析軟體和諮詢為核心的新型服務模式，這些模式支持結果解讀、品管以及與電子健康記錄的整合。總而言之，這些趨勢正在重塑整個診斷生態系統的採購重點、臨床路徑和夥伴關係。

2025年美國關稅環境對診斷供應鏈、籌資策略、臨床取得先進檢測的實際影響

美國在2025年前實施的關稅和貿易措施，已對診斷設備和試劑的供應鏈造成了實際的摩擦。進口關稅及相關合規要求推高了某些設備和耗材的成本，影響了採購週期，並促使一些實驗室和醫院重新評估其供應商多元化策略。為此，採購團隊越來越重視本地庫存緩衝和能夠緩解關稅波動的合約條款，而製造商則在評估本土生產和近岸外包，以降低跨境關稅帶來的影響。

由於這種轉變，商業策略正在調整，以維持醫療服務的連續性，並確保患者能夠獲得定序儀、成像系統和專用染色試劑等關鍵檢測工具。製造商和經銷商正在重新談判經銷商協議，並探索聯合承包模式以穩定供應。對於臨床領導者而言，關稅環境凸顯了供應鏈彈性規劃和基於情境的預算編制的重要性，這些規劃和預算編制需考慮監管和貿易主導的成本，同時確保診斷品質和患者能夠及時獲得檢測。

從技術架構、產品系列、生物標記、樣本類型和最終用戶需求等方面獲取可操作的細分洞察，以指南優先排序。

了解市場區隔對於使產品開發和商業化與臨床需求和購買行為保持一致至關重要。技術細分揭示了切片檢查、組織病理學、影像學和分子診斷領域截然不同的動態。切片檢查需求因穿刺和手術方法而異，這兩種方法都會影響樣本完整性和下游檢測的適用性。組織病理學工作流程因免疫組織化學和染色系統而異，每種方法都需要客製化的試劑組合和自動化選項。數位乳房斷層合成、乳房X光攝影、MRI和超音波等影像技術在篩檢和診斷管道中定位日益明確，包括資本投資和培訓方面的影響。分子診斷包括FISH、基於PCR的方法和次世代定序儀，其中靶向NGS和全基因組定序對數據分析和實驗室基礎設施提出了不同的要求。基於PCR的方法在靈敏度和通量方面又可分為數位PCR和即時PCR。

產品細分進一步細化了耗材、儀器、軟體和服務等方面的責任。試劑和玻片等耗材對經常性收入和物流較為敏感，而從切片檢查設備和組織病理學儀器到成像系統和定序儀等儀器則需要長期的服務和升級策略。諮詢、維護和數據分析平台等軟體和服務對於從複雜資料集中提取臨床價值至關重要。生物標記細分涵蓋 BRCA、ER/PR、HER2 和 Ki-67 等，有助於確定檢測方法開發的優先順序，並支持伴隨診斷的臨床效用。血液、血清和組織等檢體類型會影響分析前工作流程、穩定性方案以及適當的分子和影像方法的選擇。最後，針對癌症研究中心、診斷實驗室、醫院和專科診所的終端用戶細分，凸顯了從研究級檢測到高性能臨床診斷等各種適用解決方案的需求。

美洲、歐洲、中東和非洲以及亞太地區之間的區域需求和應用差異將決定臨床應用和商業策略。

區域動態正在影響全球的技術應用、監管管道和報銷機制。在美洲，強大的臨床研究網路和醫院系統支援先進影像和分子診斷平台的快速普及，而供應鏈因素和政策變化則影響採購行為。歐洲、中東和非洲的情況則截然不同。西歐市場通常在整合數位病理和綜合生物標記檢測方面處於領先地位，但該地區的新興市場面臨基礎設施和准入方面的限制，因此優先考慮成本效益高且可靠的診斷方式。監管協調工作和跨境合作正在逐步加快創新從研究到實踐的轉化速度。

在亞太地區，基礎設施的快速發展和對醫療技術的巨額投資正在加速高性能分子檢測工具和成像解決方案的普及，尤其注重可擴展性和本地化生產。不同地區的報銷機制、勞動力供應以及集中式與分散式檢測模式的差異是影響技術應用的關鍵因素。因此，商業策略必須因地制宜，在標準化的全球價值主張與反映當地臨床工作流程和監管要求的客製化實施提案之間取得平衡。

競爭定位、夥伴關係和臨床檢驗如何重新定義乳癌診斷技術和服務領域的領導地位

乳癌診斷領域的競爭格局由傳統設備供應商、新興分子診斷專家和數位醫療參與企業組成。現有企業持續投資於影像系統、切片檢查設備和組織病理學儀器的漸進式創新，而新參與企業則專注於小眾分子檢測、標靶定序平台和軟體主導的解讀工具。對於那些尋求將硬體功能與分析軟體和資訊服務相結合，以提供端到端診斷解決方案的公司而言，策略夥伴關係和共同開發契約正變得越來越普遍。

此外，透過針對性地收購利基技術供應商以及與臨床網路建立合作關係來實現整合，正在重塑市場策略。強大的售後服務和培訓課程能夠使供應商脫穎而出，尤其對於需要持續維護和驗證的複雜設備而言更是如此。取得高品質、經過篩選的臨床資料集，並透過同行評審的研究和真實世界證據來證明其臨床效用，是至關重要的競爭優勢。最終，能夠整合強大的臨床檢驗、可擴展的生產能力和快速響應的商業支援的公司，將最有希望贏得與醫院、實驗室和專科診所的長期合約。

為製造商、臨床領導者和支付者提供切實可行、影響深遠的建議，以加速臨床應用，同時保障營運彈性。

產業領導者應優先考慮兼顧臨床影響和營運可擴展性的投資。首先，製造商應加快影像處理平台、實驗室儀器和分子分析之間的整合，以建立一個可互通的生態系統，從而簡化臨床醫生的工作流程並減少交接環節。其次，改善服務模式，例如預測性維護、培訓和數據主導諮詢，可以提高客戶維繫並降低機構投資者的整體擁有成本。第三，企業應建構模組化產品套件，使醫院和實驗室能夠在不中斷核心臨床服務的情況下逐步升級和添加功能。

從臨床角度來看，相關人員必須重視檢測標準化和跨部門培訓，以確保影像學和分子檢測結果解讀的一致性。供應鏈多元化和區域庫存策略可降低關稅和貿易風險，同時保障關鍵耗材和設備的供應。最後，支付方和醫療系統應儘早參與，制定以金額為準的報銷機制，充分認可精準診斷的後續益處，例如減少過度治療和改善治療方法匹配。採取這些措施將有助於新技術的持續應用，並最大限度地發揮其臨床效用。

一個穩健的混合方法研究框架，結合了初步臨床見解、監管分析和工作流程圖譜，以支援策略診斷情報。

本研究整合了同行評審文獻、監管指導文件、臨床實驗室註冊資訊以及對臨床實驗室技術人員、病理學家、放射科醫生和採購負責人的訪談，從而對診斷現狀進行了全面的分析。研究採用定量數據與定性見解相結合的方式，確保對技術成熟度、臨床效用和商業性可行性進行平衡的解讀。調查方法著重於繪製切片檢查、組織病理學、影像學和分子診斷的工作流程圖，並考察了耗材、儀器和軟體服務的產品生命週期，以識別瓶頸和整合機會，並了解售後市場動態。

透過對技術規格、監管許可和設備標籤進行交叉驗證，以及專家檢驗會議以確認臨床有效性，確保了數據品質。區域分析納入了美洲、歐洲、中東和非洲以及亞太地區的法律規範和報銷模式，以反映不同的實施場景。研究結果盡可能輔以用例和實際案例，以確保策略建議具有實際操作意義。

對融合診斷模式的策略概述以及將創新轉化為臨床影響所需的營運前提條件

總之，乳癌診斷領域正朝著影像學、組織學分析和分子譜分析的緊密整合方向發展，並輔以軟體和服務，實現數據驅動的臨床決策。這些整合模式為提高診斷準確性、實現個人化治療選擇和簡化治療流程創造了機遇，但也需要完善的營運規劃和跨臨床專科的協作模式。投資於互通性、臨床檢驗和區域性商業性模式的相關人員將更有能力將技術前景轉化為可衡量的患者獲益。

展望未來，穩健的供應鏈、靈活的監管策略以及對支付方的顯著價值將是持續推廣的關鍵推動因素。透過將產品藍圖與實際臨床工作流程相契合，並儘早與終端用戶和支付方進行溝通，診斷創新者和醫療系統可以加速高價值技術的應用，同時確保及時、準確的乳癌診斷服務的公平獲取。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 利用機器學習演算法增強數位乳房攝影中的病灶偵測
  • 擴大循環腫瘤DNA液態生物檢體檢測規模，用於早期乳癌監測
  • 整合以患者為中心的行動醫療平台，用於追蹤治療依從性
  • 監管部門核准推進HER2和PIK3CA標靶治療伴隨診斷
  • 實施結合遺傳和影像生物標記的風險分層模型
  • 開發3D自動化乳房超音波系統以提高緻密組織的檢出率
  • 利用遠距離診斷和遠端醫療就診的去中心化臨床檢測的出現
  • 擴大支付方獎勵和乳癌預防篩檢的報銷框架

第6章美國關稅的累積影響，2025年

第7章 人工智慧的累積影響，2025年

第8章乳癌診斷市場（依技術分類）

  • 切片檢查
    • 針刺切片
    • 手術切片檢查
  • 組織病理學
    • 免疫組織化學
    • 染色系統
  • 影像
    • 數位乳房斷層合成
    • 乳房X光檢查
    • MRI
    • 超音波
  • 分子診斷
    • FISH
    • NGS
      • 標靶NGS
      • 全基因組序列分析
    • 基於PCR的
      • 數位PCR
      • 即時PCR

第9章乳癌診斷產品市場

  • 消耗品
    • 試劑和套件
    • 玻片和染色試劑
  • 裝置
    • 切片檢查裝置
    • 組織病理學設備
    • 影像系統
    • 序列器
  • 軟體和服務
    • 諮詢和維護
    • 數據分析軟體

第10章乳癌診斷市場（依生物標記分類）

  • BRCA
  • ER/PR
  • HER2
  • Ki-67

第11章 依樣本類型分類的乳癌診斷市場

  • 血
  • 血清
  • 組織

第12章乳癌診斷市場（依最終用戶分類）

  • 癌症研究中心
  • 診斷實驗室
  • 醫院
  • 專科診所

第13章乳癌診斷市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章乳癌診斷市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國乳癌診斷市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • F. Hoffmann-La Roche Ltd.
    • GE HealthCare Technologies GmbH
    • Siemens Healthineers AG
    • Hologic, Inc.
    • Koninklijke Philips NV
    • Thermo Fisher Scientific Inc.
    • Abbott Laboratories
    • QIAGEN NV
    • Illumina, Inc.
    • Becton, Dickinson and Company
Product Code: MRR-A26E0E57405A

The Breast Cancer Diagnostics Market is projected to grow by USD 13.06 billion at a CAGR of 8.02% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 7.04 billion
Estimated Year [2025] USD 7.60 billion
Forecast Year [2032] USD 13.06 billion
CAGR (%) 8.02%

A concise orientation to the evolving breast cancer diagnostics landscape highlighting crossroads between clinical utility and operational transformation

Breast cancer diagnostics are undergoing a period of rapid transformation driven by parallel advances in sampling techniques, tissue analytics, imaging technologies, and molecular profiling. Emerging tools are reshaping clinical pathways from initial screening through definitive diagnosis and therapeutic stratification, while multidisciplinary collaboration between radiology, pathology, and molecular laboratories is increasingly essential to deliver precision care. Clinical decision-making is being augmented by richer data streams, including digital breast tomosynthesis images, immunohistochemistry slides digitized for algorithmic review, and genomic signatures from next-generation sequencing, all of which create both opportunity and complexity for providers and industry.

Against this backdrop, stakeholders must reconcile operational constraints with evolving standards of care. Adoption dynamics differ across end users such as cancer research centers, diagnostic laboratories, hospitals, and specialized clinics, and they are influenced by product segmentation spanning consumables, instruments, and software and services. Sample type considerations, whether blood, serum, or tissue, will continue to dictate workflow design and specimen logistics. In sum, the diagnostic landscape requires integrated strategic planning that balances clinical utility, workflow efficiency, and sustainable reimbursement pathways.

How advances in imaging, tissue sampling, histopathology automation, and molecular profiling are systematically redefining diagnostic pathways and clinical workflows

Several transformative shifts are changing how breast cancer is detected, classified, and monitored. First, imaging is moving from analogue to digital-first ecosystems, where digital breast tomosynthesis and advanced mammography are complemented by MRI and ultrasound to enhance lesion characterization and triage. These imaging modalities are increasingly integrated with computational tools that augment radiologist interpretation and prioritize cases for biopsy. Second, biopsy approaches are diversifying as needle and surgical techniques are refined to maximize tissue preservation while enabling comprehensive downstream testing, which in turn affects laboratory workflows and consumable demand.

Meanwhile, histopathology is evolving through greater adoption of immunohistochemistry and automated staining systems that increase throughput and reproducibility. Molecular diagnostics are also rising in clinical prominence; fluorescence in situ hybridization, PCR variants, and next-generation sequencing, including targeted panels and whole genome approaches, are delivering granular biomarker insights that drive therapeutic decisions. Complementing these technological shifts are new service models around data analysis software and consulting that support interpretation, quality control, and integration with electronic medical records. Collectively, these trends are reshaping procurement priorities, clinical pathways, and partnerships across the diagnostic ecosystem.

Practical implications of the United States tariff environment in 2025 on diagnostic supply chains, procurement strategies, and clinical access to advanced testing

Tariff policies and trade measures in the United States for 2025 have introduced practical friction into the supply chains that underpin diagnostic device and reagent availability. Import duties and related compliance requirements have elevated the cost of certain instruments and consumables, affecting procurement timelines and prompting some laboratories and hospitals to reassess supplier diversification strategies. In response, procurement teams are increasingly emphasizing localized inventory buffers and contractual clauses that mitigate tariff volatility, while manufacturers are evaluating onshore production and nearshoring to reduce exposure to cross-border tariff impacts.

As a result of these shifts, commercial strategies are adapting to preserve continuity of care and maintain access to critical testing modalities such as sequencers, imaging systems, and specialized staining reagents. Manufacturers and distributors are negotiating revised reseller agreements and exploring collaborative consignment models to stabilize supply. For clinical leaders, the tariff environment underscores the importance of supply chain resilience planning and scenario-based budgeting that account for regulatory and trade-driven costs, without compromising diagnostic quality or patient access to timely testing.

Actionable segmentation insights across technology architectures, product portfolios, biomarkers, sample types, and end-user demands to guide prioritization

Understanding market segmentation is essential to align product development and commercialization with clinical needs and purchasing behavior. Technology segmentation reveals distinct dynamics across biopsy, histopathology, imaging, and molecular diagnostics. Biopsy demand is differentiated by needle and surgical approaches, each influencing sample integrity and downstream assay compatibility. Histopathology workflows are bifurcated by immunohistochemistry and staining systems that require tailored reagent portfolios and automation options. Imaging modalities including digital breast tomosynthesis, mammography, MRI, and ultrasound are being positioned differently across screening and diagnostic pathways, with implications for capital investment and training. Molecular diagnostics encompass FISH, PCR-based methods, and next-generation sequencing, where targeted NGS and whole genome sequencing create divergent demands for data analysis and laboratory infrastructure, and PCR-based approaches split between digital PCR and real-time PCR in terms of sensitivity and throughput.

Product segmentation further delineates responsibilities across consumables, instruments, and software and services. Consumables such as reagents and slides have recurring revenue profiles and logistics sensitivities, whereas instruments-ranging from biopsy devices and histopathology instruments to imaging systems and sequencers-require long-term service and upgrade strategies. Software and services, including consulting, maintenance, and data analysis platforms, are increasingly important to extract clinical value from complex datasets. Biomarker segmentation, spanning BRCA, ER/PR, HER2, and Ki-67, dictates assay development priorities and informs clinical utility claims for companion diagnostics. Sample type considerations-blood, serum, and tissue-impact pre-analytical workflows, stability protocols, and the selection of appropriate molecular or imaging approaches. Finally, end user segmentation, covering cancer research centers, diagnostic laboratories, hospitals, and specialized clinics, highlights the need for adaptable solutions that can scale from research-grade assays to high-throughput clinical diagnostics.

Regional imperatives and adoption differentials across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine clinical adoption and commercial strategy

Regional dynamics shape technology adoption, regulatory pathways, and reimbursement practices across the globe. In the Americas, strong clinical research networks and hospital systems are supporting rapid uptake of advanced imaging and molecular diagnostic platforms, while supply chain considerations and policy shifts are influencing procurement behavior. Europe, the Middle East & Africa present a heterogeneous picture: Western European markets often lead in integrating digital pathology and comprehensive biomarker testing, while emerging markets in the region face infrastructure and access constraints that prioritize cost-effective and robust diagnostic modalities. Regulatory harmonization efforts and cross-border collaborations are gradually altering the pace at which innovations move from research to practice.

In the Asia-Pacific region, rapid infrastructure development and significant investments in healthcare technology are accelerating adoption of high-throughput molecular tools and imaging solutions, with an emphasis on scalability and localized manufacturing. Across all regions, differences in reimbursement frameworks, workforce capacity, and centralized versus decentralized laboratory models are the primary determinants of technology diffusion. Consequently, commercial strategies must be regionally nuanced, balancing standardized global value propositions with tailored implementations that reflect local clinical workflows and regulatory expectations.

How competitive positioning, partnerships, and clinical validation are redefining leadership in breast cancer diagnostic technologies and service delivery

Competitive dynamics in breast cancer diagnostics are defined by a mix of legacy instrument providers, emerging molecular specialists, and digital health entrants. Incumbent manufacturers continue to invest in incremental innovation for imaging systems, biopsy devices, and histopathology instrumentation, while newer entrants focus on niche molecular assays, targeted sequencing panels, and software-driven interpretation tools. Strategic partnerships and co-development agreements are increasingly common as companies seek to pair hardware capabilities with analytic software and data services to deliver end-to-end diagnostic solutions.

Moreover, consolidation through targeted acquisition of niche technology providers and alliances with clinical networks is reshaping go-to-market strategies. Strong aftermarket services and training programs are differentiating suppliers, especially for complex instruments that require ongoing maintenance and validation. Access to high-quality, curated clinical datasets and the ability to demonstrate clinical utility through peer-reviewed studies and real-world evidence are essential competitive advantages. Ultimately, companies that can integrate robust clinical validation, scalable manufacturing, and responsive commercial support will be best positioned to capture long-term engagement with hospitals, laboratories, and specialized clinics.

Practical, high-impact recommendations for manufacturers, clinical leaders, and payers to accelerate clinical adoption while safeguarding operational resilience

Industry leaders should prioritize investments that align clinical impact with operational scalability. First, manufacturers should accelerate integration between imaging platforms, laboratory instrumentation, and molecular analytics to create interoperable ecosystems that simplify clinician workflows and reduce handoffs. Second, enhancing service models-through predictive maintenance, training, and data-driven consulting-will increase customer retention and lower the total cost of ownership for institutional buyers. Third, companies should build modular product offerings that allow hospitals and laboratories to phase upgrades and add capabilities without disrupting core clinical services.

From a clinical perspective, stakeholders must emphasize assay standardization and cross-disciplinary training to ensure consistent interpretation of imaging and molecular results. Supply chain diversification and localized inventory strategies can mitigate tariff and trade risk while preserving access to critical consumables and instruments. Finally, payers and health systems should be engaged early to define value-based reimbursement pathways that recognize the downstream benefits of precise diagnostics, including reduced overtreatment and improved therapy matching. Taken together, these measures will enable sustainable adoption and maximize the clinical utility of emerging diagnostic innovations.

A robust mixed-methods research framework combining primary clinical insights, regulatory analysis, and workflow mapping to underpin strategic diagnostics intelligence

This research synthesized peer-reviewed literature, regulatory guidance documents, clinical trial registries, and primary interviews with clinical laboratorians, pathologists, radiologists, and procurement leaders to create a holistic diagnostic landscape analysis. Quantitative inputs were triangulated with qualitative insights to ensure balanced interpretation of technology readiness, clinical utility, and commercial feasibility. The methodology placed particular emphasis on workflow mapping across biopsy, histopathology, imaging, and molecular diagnostics to identify bottlenecks and integration opportunities, and it examined product life cycles for consumables, instruments, and software-enabled services to understand aftermarket dynamics.

Data quality was assured through cross-validation of technical specifications, regulatory clearances, and device labeling, coupled with expert validation sessions to confirm clinical relevance. Regional analyses incorporated regulatory frameworks and reimbursement paradigms across the Americas, Europe, Middle East & Africa, and Asia-Pacific to reflect diverse adoption scenarios. Where possible, findings were corroborated with case studies and implementation examples to ground strategic recommendations in operational reality.

A strategic summation of converging diagnostic modalities and the operational prerequisites needed to translate innovation into clinical impact

In conclusion, the breast cancer diagnostics field is moving toward tighter integration of imaging, tissue-based analyses, and molecular profiling, supported by software and services that enable data-driven clinical decisions. These converging modalities are creating opportunities to refine diagnostic accuracy, personalize treatment selection, and streamline care pathways, but they also necessitate robust operational planning and collaborative models across clinical specialties. Stakeholders that invest in interoperability, clinical validation, and regionally adapted commercial approaches will be best positioned to translate technological promise into measurable patient benefit.

Looking forward, resilience in supply chains, agility in regulatory strategy, and demonstrable value to payers will be critical enablers of sustainable adoption. By aligning product roadmaps with real-world clinical workflows and by engaging early with end users and payers, diagnostic innovators and health systems can accelerate the adoption of high-value technologies while maintaining equitable access to timely and accurate breast cancer diagnosis.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of machine learning algorithms for enhanced lesion detection in digital mammography
  • 5.2. Expansion of circulating tumor DNA liquid biopsy tests for early breast cancer monitoring
  • 5.3. Integration of patient-centric mobile health platforms for treatment adherence tracking
  • 5.4. Regulatory approvals driving companion diagnostics for targeted HER2 and PIK3CA therapies
  • 5.5. Implementation of risk stratification models combining genetics and imaging biomarkers
  • 5.6. Development of 3D automated breast ultrasound systems to improve detection rates in dense tissue
  • 5.7. Emergence of decentralized clinical trials leveraging remote diagnostics and telehealth visits
  • 5.8. Growing payer incentives and reimbursement frameworks for preventive breast cancer screening

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Breast Cancer Diagnostics Market, by Technology

  • 8.1. Biopsy
    • 8.1.1. Needle Biopsy
    • 8.1.2. Surgical Biopsy
  • 8.2. Histopathology
    • 8.2.1. Immunohistochemistry
    • 8.2.2. Staining Systems
  • 8.3. Imaging
    • 8.3.1. Digital Breast Tomosynthesis
    • 8.3.2. Mammography
    • 8.3.3. MRI
    • 8.3.4. Ultrasound
  • 8.4. Molecular Diagnostics
    • 8.4.1. FISH
    • 8.4.2. NGS
      • 8.4.2.1. Targeted NGS
      • 8.4.2.2. Whole Genome Sequencing
    • 8.4.3. PCR-Based
      • 8.4.3.1. Digital PCR
      • 8.4.3.2. Real-Time PCR

9. Breast Cancer Diagnostics Market, by Product

  • 9.1. Consumables
    • 9.1.1. Reagents And Kits
    • 9.1.2. Slides And Staining Reagents
  • 9.2. Instruments
    • 9.2.1. Biopsy Devices
    • 9.2.2. Histopathology Instruments
    • 9.2.3. Imaging Systems
    • 9.2.4. Sequencers
  • 9.3. Software And Services
    • 9.3.1. Consulting And Maintenance
    • 9.3.2. Data Analysis Software

10. Breast Cancer Diagnostics Market, by Biomarker

  • 10.1. BRCA
  • 10.2. ER/PR
  • 10.3. HER2
  • 10.4. Ki-67

11. Breast Cancer Diagnostics Market, by Sample Type

  • 11.1. Blood
  • 11.2. Serum
  • 11.3. Tissue

12. Breast Cancer Diagnostics Market, by End User

  • 12.1. Cancer Research Centers
  • 12.2. Diagnostic Laboratories
  • 12.3. Hospitals
  • 12.4. Specialized Clinics

13. Breast Cancer Diagnostics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Breast Cancer Diagnostics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Breast Cancer Diagnostics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. F. Hoffmann-La Roche Ltd.
    • 16.3.2. GE HealthCare Technologies GmbH
    • 16.3.3. Siemens Healthineers AG
    • 16.3.4. Hologic, Inc.
    • 16.3.5. Koninklijke Philips N.V.
    • 16.3.6. Thermo Fisher Scientific Inc.
    • 16.3.7. Abbott Laboratories
    • 16.3.8. QIAGEN N.V.
    • 16.3.9. Illumina, Inc.
    • 16.3.10. Becton, Dickinson and Company

LIST OF FIGURES

  • FIGURE 1. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BREAST CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. BREAST CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BREAST CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NEEDLE BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NEEDLE BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NEEDLE BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NEEDLE BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NEEDLE BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NEEDLE BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SURGICAL BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SURGICAL BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SURGICAL BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SURGICAL BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SURGICAL BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SURGICAL BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY STAINING SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY STAINING SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY STAINING SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY STAINING SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY STAINING SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY STAINING SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL BREAST TOMOSYNTHESIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL BREAST TOMOSYNTHESIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL BREAST TOMOSYNTHESIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL BREAST TOMOSYNTHESIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL BREAST TOMOSYNTHESIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL BREAST TOMOSYNTHESIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MAMMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MAMMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MAMMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MAMMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MAMMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MAMMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY FISH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY FISH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY FISH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY FISH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY FISH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY FISH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TARGETED NGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TARGETED NGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TARGETED NGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TARGETED NGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TARGETED NGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TARGETED NGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REAL-TIME PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REAL-TIME PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REAL-TIME PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REAL-TIME PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REAGENTS AND KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REAGENTS AND KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REAGENTS AND KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REAGENTS AND KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REAGENTS AND KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REAGENTS AND KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SLIDES AND STAINING REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SLIDES AND STAINING REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SLIDES AND STAINING REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SLIDES AND STAINING REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SLIDES AND STAINING REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SLIDES AND STAINING REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SEQUENCERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SEQUENCERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SEQUENCERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SEQUENCERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SEQUENCERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SEQUENCERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSULTING AND MAINTENANCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSULTING AND MAINTENANCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSULTING AND MAINTENANCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSULTING AND MAINTENANCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSULTING AND MAINTENANCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSULTING AND MAINTENANCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BRCA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BRCA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BRCA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BRCA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BRCA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BRCA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ER/PR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ER/PR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ER/PR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ER/PR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ER/PR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ER/PR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HER2, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HER2, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HER2, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HER2, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HER2, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HER2, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY KI-67, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY KI-67, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY KI-67, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY KI-67, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY KI-67, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY KI-67, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SERUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SERUM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SERUM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SERUM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SERUM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TISSUE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TISSUE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TISSUE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TISSUE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TISSUE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TISSUE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER RESEARCH CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER RESEARCH CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER RESEARCH CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER RESEARCH CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER RESEARCH CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER RESEARCH CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SPECIALIZED CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SPECIALIZED CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SPECIALIZED CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SPECIALIZED CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2025-2032 (USD MILLION)
  • TABLE 291. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 292. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 293. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, 2018-2024 (USD MILLION)
  • TABLE 294. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, 2025-2032 (USD MILLION)
  • TABLE 295. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, 2018-2024 (USD MILLION)
  • TABLE 296. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, 2025-2032 (USD MILLION)
  • TABLE 297. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 298. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 299. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 300. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 301. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 302. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 303. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2024 (USD MILLION)
  • TABLE 304. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2025-2032 (USD MILLION)
  • TABLE 305. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2024 (USD MILLION)
  • TABLE 306. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2025-203